Therapies for Chronic Inflammatory Demyelinating Polyneuropathy Using Interferon-Beta
AssigneeBiogen Idec MA Inc.
InventorAlfred Sandrock
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for the treatment, and pharmaceuticals for the use in the treatment, of mammalian subjects having, or at risk of developing, chronic demyelinating neuropathies, e.g., CIDP. The methods involve the administration of IFN-β therapeutics.
Claims74
Use of an IFN-β therapeutic in the manufacture of a medicament for the treatment of a chronic demyelinating motor neuropathy.
A method for treating a chronic demyelinating motor neuropathy in a mammal, comprising administering to the mammal a therapeutically effective amount of an IFN-β therapeutic.
The method of any one of claims 37-60, comprising administering to the mammal several doses of an IFN-β therapeutic.
A method for treating CIDP, comprising administering to a subject having CIDP a pharmaceutically effective amount of an IFN-β therapeutic and further administering to the subject an immunosuppressant or subjecting the subject to plasmapheresis.
A method for treating CIDP, comprising administering to a subject having CIDP a pharmaceutically effective amount of an IFN-β therapeutic in combination with a second CIDP treatment, wherein administration of the IFN-β therapeutic is via a non-subcutaneous parenteral route.
A method for treating CIDP, comprising administering to a subject having CIDP a pharmaceutically effective amount of an IFN-β therapeutic in combination with a second CIDP treatment, wherein administration of the IFN-β therapeutic is weekly.
In a method of treating CIDP in a subject receiving a first CIDP treatment selected from the group consisting of administration of a steroid;
- administration of an anti-inflammatory drug;
- administration of IVIG and plasmapheresis, the improvement comprising administering to the subject, in addition to the first CIDP treatment, a dose of an IFN-β therapeutic in an amount effective to significantly reduce the dose or frequency of the first CIDP treatment, wherein administration of the IFN-β therapeutic is via a non-subcutaneous parenteral route, to provide effective relief from symptoms of CIDP.
In a method of treating CIDP in a subject receiving a first CIDP treatment selected from the group consisting of administration of a steroid;
- administration of an anti-inflammatory drug;
- administration of IVIG and plasmapheresis, the improvement comprising administering to the subject, in addition to the first CIDP treatment, once a week a dose of an IFN-β therapeutic in an amount effective to significantly reduce the dose or frequency of the first CIDP treatment, to provide effective relief from symptoms of CIDP.
In a method of treating CIDP in a subject receiving a first CIDP treatment selected from the group consisting of administration of a steroid;
- administration of an anti-inflammatory drug;
- and plasmapheresis, the improvement comprising administering to the subject, in addition to the first CIDP treatment, a dose of an IFN-β therapeutic in an amount effective to significantly reduce the dose or frequency of the first CIDP treatment, to provide effective relief from symptoms of CIDP.
Dependencies are inferred from the claim text.